Todos os posts

Throughout the history of medicine, major breakthroughs have often come from asking new questions about old problems. In recent years, something similar has been happening in the field of mental health. Even with the development of many effective medications throughout the 20th century, several psychiatric conditions remain difficult to treat. Treatment-resistant depression, trauma-related disorders, and substance dependence are examples of conditions that still present impor

Mental health is no longer just a clinical issue; it has become a structural matter of economic development, social stability, and scientific innovation. Global reports, epidemiological studies, and economic analyses published in recent years indicate that mental disorders and substance use disorders are among the leading causes of disability worldwide, with direct impacts on productivity, healthcare systems, and public policy. In 2026, the international landscape points to t

For decades, clinical psychiatry lived with a paradox: while knowledge about the brain advanced rapidly in fields such as neuroimaging, genetics, and experimental neuroscience, the development of new psychiatric treatments progressed more slowly. Many available therapeutic options were variations of mechanisms discovered in the last century, primarily based on modulation of classical neurotransmitters. This scenario led specialists to characterize the period as one of relativ

Mental health is no longer a peripheral topic in public debate. It has moved to the center of discussions about quality of life, productivity, public policy, and innovation investment. Recent data indicate that a significant share of Brazilians intend to increase their spending on mental health in the coming years, reflecting a deep behavioral shift: caring for the mind is now seen as essential as caring for the body. This movement follows a global trend: people are becoming

Mental health has moved from a peripheral issue to one of the main public health challenges of the 21st century. In Brazil, the rise in depressive, anxiety-related and substance use disorders impacts not only individuals and families, but also productivity, the sustainability of the healthcare system and social development. In this context, Brazil’s national mental health policy is going through a decisive moment: the transition from a historically fragmented model to an appr

Discussions about SUS costs  are often framed in a simplified way: how to spend less within a public healthcare system that faces chronic underfunding, high care demand, and widely recognized operational constraints. Throughout this text, when we refer to the SUS, we are referring to the Brazilian Unified Health System as it operates in practice , with its achievements, challenges, and inherent complexity. In this context, reducing SUS costs  does not mean merely cutting expe

The introduction of new therapies into clinical practice is a complex and careful process, above all deeply guided by medical ethics . Unlike other sectors, innovation in healthcare cannot be driven solely by technological speed, economic interest, or social enthusiasm. It requires rigorous criteria, scientific responsibility, and a continuous commitment to patient safety. In this context, the adoption of new therapeutic approaches involves the coordinated work of different h

Brazil’s public healthcare system faces one of the greatest challenges of its recent history: ensuring universal, comprehensive, and equitable access to care in a context of limited financial resources, population growth, an aging society, and a significant rise in chronic diseases. The Unified Health System (SUS), internationally recognized for its scale and complexity, operates under constant pressure to deliver efficiency, budget predictability, and improved clinical outco

The renewed interest in psychedelics is neither an isolated cultural phenomenon nor a passing trend. It emerges from a real and persistent crisis in current mental health treatment models. Conditions such as treatment-resistant depression, substance use disorders, and other severe psychiatric illnesses continue to show high rates of refractoriness, relapse, and significant adverse effects, even after decades of reliance on traditional psychopharmacological therapies. Within t

Transforming natural substances—especially those of botanical origin—into a regulated medicine is a long, highly technical, and deeply strategic process. It is a journey involving science, biotechnology, clinical validation, and a rigorous regulatory pathway defined by agencies such as ANVISA  and the FDA . Understanding this pathway is not just scientific curiosity: it means recognizing where value is created, which risks are eliminated at each stage, and why companies that

The global natural-products landscape is growing rapidly, but very few products are able to generate real clinical evidence  capable of transforming patient outcomes. This is the fundamental divide between dietary supplements  and prescription phytomedicines , and the reason Ayamed chose the regulated pharmaceutical route. While supplements occupy retail shelves without needing to prove therapeutic effect, clinical evidence  is mandatory for any regulated botanical drug. And

Indigenous Lands, biodiversity and human health Indigenous Lands are often seen as areas of environmental preservation and cultural rights. Yet, at a time when the world is rediscovering the value of natural medicines, protecting these territories has an even more direct meaning: ensuring the survival of plant species that are essential for human health , especially in the field of mental health. More than an ethical or environmental issue, preserving Indigenous Lands also me

Introduction: the urgency of new solutions Mental health is facing a silent crisis. Depression, anxiety, and substance dependence rank among the world’s largest public health issues, with immense human and economic impact. In Brazil, more than 20 million people suffer from depression; in the United States, the annual costs of mental disorders and substance abuse reach hundreds of billions of dollars. Current treatments, mainly based on antidepressants and anxiolytics, present

Brazil is at a turning point in healthcare. The prevalence of mental health disorders such as depression and anxiety, and the growing...

The Scope of the Problem The treatment of major depressive disorder  remains one of the greatest challenges in 21st-century mental...

In recent years, modern science has rediscovered the therapeutic potential of psychedelics. Substances that, since the 1970s, had been...

Phyto therapeutics  have been gaining ground in global medicine by representing the convergence between popular tradition and regulated...

The development of herbal pharmaceuticals  represents both one of the greatest challenges and one of the most promising opportunities in...

Depression is one of the most common and disabling mental health conditions worldwide, but not all patients respond satisfactorily to the...

Chemical dependency is one of the most complex public health challenges of our time. More than a matter of individual behavior, it is a...